Medtronic reports positive results from OpT2mise trial in people with type 2 diabetes

2 July 2014 (Last Updated November 22nd, 2018 11:24)

US-based Medtronic has reported results of the OpT2mise trial, which demonstrated that MiniMed insulin pumps safely achieve better glucose control for people with insulin-requiring type 2 diabetes than multiple daily injections.

US-based Medtronic has reported results of the OpT2mise trial, which demonstrated that MiniMed insulin pumps safely achieve better glucose control for people with insulin-requiring type 2 diabetes than multiple daily injections.

The OpT2mise trial evaluated the comparative efficacy of insulin pump therapy versus multiple daily insulin injections in people with type 2 diabetes with poor glycemic control.

In the trial, patients using insulin pumps achieved a mean A1C (average blood glucose) reduction of 1.1% compared with only a 0.4% reduction by those using multiple daily injections.

"These trial results are important in showing that insulin pump therapy can safely reduce A1C without causing hypoglycemic episodes and could redefine the standard of care for the growing population of insulin-requiring type 2 diabetes patients."

Medtronic said that the improvement in glucose control was achieved without any episodes of severe hypoglycaemia, while patients in the insulin pump group lowered the total daily dose of insulin by more than 20%.

No difference in weight gain was observed in patients between the two groups.

According to the company, reducing A1C is important for diabetes people because even small percent drops aid significantly in preventing complications such as eye disease, kidney disease, nerve damage and heart attacks.

University Hospital of Caen lead professor on the study Yves Reznik said: "This patient population is sizeable and difficult to manage, which frequently results in costly complications. For these patients, insulin pumps are an essential new treatment option and have now scientifically been proven to show significant benefits.

"These trial results are important in showing that insulin pump therapy can safely reduce A1C without causing hypoglycemic episodes and could redefine the standard of care for the growing population of insulin-requiring type 2 diabetes patients."

The Medtronic-sponsored global, randomised, controlled trial was conducted with participation from 331 patients, with 168 randomised to pump treatment and 163 to multiple daily injections.

Medtronic Diabetes chief medical officer and vic-president of global, clinical and medical affairs Francine Kaufman said: "OpT2mise is the latest example of this clinical leadership and a trial that has the potential to help improve access to insulin pump therapy for the many people with type 2 diabetes who could benefit."